
  
    
      
        
        The_DT pathologist_NN makes_NNS do_VBP with_IN red_JJ wine_NN until_IN an_DT effective_JJ drug_NN is_VBZ available_JJ ,_, the_DT
        biochemist_NN discards_NNS the_DT bread_NN from_IN her_PRP$ sandwiches_NNS ,_, and_CC the_DT mathematician_NN indulges_VBZ in_IN
        designer_NN chocolate_NN with_IN a_DT clear_JJ conscience_NN ._. The_DT demographer_NN sticks_VBZ to_TO vitamin_NN supplements_NNS ,_,
        and_CC while_IN the_DT evolutionary_JJ biologist_NN calculates_VBZ the_DT compensations_NNS of_IN celibacy_NN ,_, the_DT
        population_NN biologist_NN transplants_NNS gonads_NNS ,_, but_CC so_RB far_RB only_RB those_DT of_IN his_PRP$ laboratory_NN mice_NNS ._.
        Their_PRP$ common_JJ cause_NN is_VBZ to_TO control_VB and_CC extend_VB the_DT healthy_JJ lifespan_NN of_IN humans_NNS ._. They_PRP want_VBP to_TO
        cure_VB ageing_VBG and_CC the_DT diseases_NNS that_WDT come_VBP with_IN it_PRP ._.
        “ I_PRP would_MD take_VB resveratrol_NN if_IN it_PRP were_VBD feasible_JJ ,_,” notes_VBZ David_NNP Sinclair_NNP ,_, assistant_NN
        professor_NN of_IN pathology_NN at_IN Harvard_NNP Medical_NNP School_NNP in_IN Boston_NNP ,_, Massachusetts_NNP ._. In_IN the_DT meantime_NN ,_,
        he_PRP adds_VBZ ,_, “ I_PRP do_VBP enjoy_VB a_DT glass_NN of_IN red_JJ wine_NN about_IN once_RB a_DT day_NN ._.” It_PRP was_VBD Sinclair_NNP 's_POS laboratory_NN ,_,
        in_IN association_NN with_IN a_DT commercial_JJ partner_NN ,_, that_WDT revealed_VBD last_JJ August_NNP how_WRB the_DT team_NN had_VBD
        identified_VBN for_IN the_DT first_JJ time_NN a_DT group_NN of_IN simple_JJ organic_JJ molecules_NNS capable_JJ of_IN extending_VBG
        lifespan_NN ._. The_DT most_RBS proficient_JJ of_IN the_DT group_NN is_VBZ resveratrol_NN ,_, the_DT plant_NN polyphenol_NN found_VBD in_IN
        red_JJ wine_NN ,_, and_CC its_PRP$ discovery_NN as_IN a_DT potential_JJ elixir_NN to_TO combat_VB ageing_VBG represents_VBZ another_DT
        extraordinary_JJ advance_NN in_IN a_DT decade_NN of_IN discoveries_NNS that_WDT have_VBP revolutionised_JJ the_DT field_NN ._.
        
          
            “ These_DT molecules_NNS will_MD be_VB useful_JJ for_IN treating_VBG diseases_NNS associated_VBN with_IN
            ageing_VBG ,_, like_IN diabetes_NN and_CC Alzheimer_NNP 's_POS ._.”
          
        
      
      
        Extending_NNP Life_NNP
        Although_IN the_DT life-enhancing_JJ effects_NNS of_IN Sinclair_NNP 's_POS polyphenols_NNS are_VBP so_RB far_RB confined_VBN to_TO the_DT
        baker_NN 's_POS yeast_NN 
        Saccharomyces_NNP cerevisiae_NN ,_, the_DT work_NN suggests_VBZ that_IN researchers_NNS
        are_VBP only_RB one_CD small_JJ step_NN from_IN making_VBG a_DT giant_JJ leap_NN for_IN humankind_NN ._. “ People_NNS imagined_VBD that_IN it_PRP
        might_MD have_VB been_VBN possible_JJ ,_, but_CC few_JJ people_NNS thought_VBD that_IN it_PRP was_VBD going_VBG to_TO be_VB possible_JJ so_RB
        quickly_RB to_TO find_VB such_JJ things_NNS ,_,” says_VBZ Sinclair_NNP ._. The_DT field_NN of_IN ageing_VBG research_NN is_VBZ buzzing_VBG ._.
        Resveratrol_NNP stimulated_VBN a_DT known_VBN activator_NN of_IN increased_VBN longevity_NN in_IN yeast_NN ,_, the_DT enzyme_NN
        Sir-_NNP 2_CD ,_, and_CC thereby_RB extended_VBD the_DT organism_NN 's_POS lifespan_NN by_IN 70_CD %_NN (_( Box_NNP 1_LS )_) ._. Sir-_NNP 2_CD belongs_VBZ to_TO a_DT
        family_NN of_IN proteins_NNS with_IN members_NNS in_IN higher_JJR organisms_NNS ,_, including_VBG SIR-_NNP 2_CD ._. 1_LS ,_, an_DT enzyme_NN that_WDT
        regulates_VBZ lifespan_NN in_IN worms_NNS ,_, and_CC SIRT-_NNP 1_CD ,_, the_DT human_JJ enzyme_NN that_WDT promotes_VBZ cell_NN survival_NN
        (_( Figure_NN 1_LS )_) ._. Though_IN researchers_NNS still_RB do_VBP not_RB know_VB whether_IN SIRT-_NNP 1_CD ,_, or_CC “ Sir-_NNP 2_CD in_IN humans_NNS ,_,” as_IN
        Sinclair_NNP puts_VBZ it_PRP ,_, has_VBZ anything_NN to_TO do_VB with_IN longevity_NN ,_, there_EX is_VBZ a_DT good_JJ chance_NN that_IN it_PRP does_VBZ ,_,
        judging_VBG by_IN its_PRP$ pedigree_NN ._. In_IN any_DT event_NN ,_, resveratrol_NN proved_VBD to_TO be_VB a_DT potent_JJ activator_NN of_IN the_DT
        human_JJ enzyme_NN ._. This_DT might_MD not_RB be_VB altogether_RB surprising_JJ ,_, at_IN least_JJS not_RB now_RB ,_, given_VBN that_IN the_DT
        polyphenol_NN is_VBZ already_RB associated_VBN with_IN health_NN benefits_NNS in_IN humans_NNS ,_, notably_RB the_DT mitigation_NN of_IN
        such_JJ age-related_JJ defects_NNS as_IN neurodegeneration_NN ,_, carcinogenesis_NNS ,_, and_CC atherosclerosis_NNS ._.
        “ The_DT study_NN came_VBD out_IN from_IN a_DT pretty_RB big_JJ gamble_NN ,_,” recalls_VBZ Sinclair_NNP ,_, who_WP used_VBD the_DT human_JJ
        enzyme_NN to_TO screen_VB and_CC identify_VB molecules_NNS that_IN he_PRP expected_VBD would_MD also_RB stimulate_VB those_DT related_VBN
        enzymes_NNS in_IN lower_JJR organisms_NNS ._. Unlike_IN SIRT-_NNP 1_CD ,_, these_DT related_VBN enzymes_NNS are_VBP known_VBN to_TO increase_VB
        longevity_NN when_WRB activated_VBN ,_, usually_RB by_IN restricting_VBG the_DT organism_NN 's_POS calorie_NN intake_NN ._. Not_RB only_RB
        did_VBD they_PRP find_VBP “ a_DT whole_JJ collection_NN of_IN related_VBN polyphenols_NNS that_WDT activate_VBP ‘ Sir-_NNP 2_CD from_IN humans_NNS ,_,’
        …_NN but_CC we_PRP put_VBP them_PRP onto_IN yeast_NN ,_, justbeing_VBG the_DT simplest_JJS model_NN ,_, and_CC amazingly_RB [_NN they_PRP ]_NN did_VBD what_WP
        we_PRP were_VBD hoping_VBG [_NN they_PRP ]_NN would_MD do_VB ,_,” recalls_VBZ Sinclair_NNP ._. “ But_CC it_PRP was_VBD a_DT real_JJ long_JJ shot_NN ._.”
        Now_RB there_EX 's_VBZ great_JJ eagerness_NN in_IN the_DT Sinclair_NNP laboratory_NN to_TO complete_VB and_CC publish_VB related_VBN
        research_NN ,_, notably_RB by_IN replicating_VBG the_DT yeast_NN work_NN in_IN higher_JJR organisms_NNS ._. “ We_PRP have_VBP very_RB
        promising_JJ results_NNS in_IN 
        Drosophila_NNP ,_, which_WDT is_VBZ a_DT huge_JJ jump_NN from_IN a_DT yeast_NN cell_NN ,_,” says_VBZ
        Sinclair_NNP ._. “ So_IN we_PRP 're_VBP very_RB encouraged_VBN by_IN that_DT ._.” Publication_NNP of_IN these_DT results_NNS is_VBZ imminent_JJ ._. The_DT
        team_NN has_VBZ also_RB quickly_RB broadened_VBD its_PRP$ horizons_NNS and_CC is_VBZ already_RB testing_VBG the_DT polyphenols_NNS on_IN
        mouse_NN disease_NN models_NNS ._. “ We_PRP think_VBP we_PRP may_MD have_VB tapped_VBN into_IN a_DT cell_NN survival_NN and_CC defence_NN
        programme_NN [_NN and_CC ]_NN that_IN these_DT molecules_NNS will_MD be_VB useful_JJ for_IN treating_VBG diseases_NNS associated_VBN with_IN
        ageing_VBG ,_, like_IN diabetes_NN and_CC Alzheimer_NNP 's_POS ,_,” says_VBZ Sinclair_NNP ._. He_PRP hopes_VBZ to_TO publish_VB the_DT diabetes_NN
        results_NNS by_IN mid-_NN 2004_CD and_CC those_DT for_IN Alzheimer_NNP 's_POS by_IN the_DT end_NN of_IN the_DT year_NN ._. Harvard_NNP and_CC BIOMOL_NNP
        Research_NNP Laboratories_NNPS ,_, its_PRP$ commercial_JJ partner_NN based_VBN in_IN Pennsylvania_NNP ,_, have_VBP already_RB filed_VBN a_DT
        patent_NN application_NN for_IN the_DT use_NN of_IN “ synthetic_JJ related_VBN molecules_NNS” to_TO combat_VB diseases_NNS of_IN
        ageing—an_NN application_NN ,_, Sinclair_NNP adds_VBZ ,_, “ very_RB much_RB linked_VBN to_TO the_DT [_NN polyphenols_NNS ]_NN paper_NN ._.”
        There_EX 's_VBZ been_VBN a_DT radical_JJ shift_NN in_IN attitude_NN towards_IN ageing_VBG ,_, says_VBZ Sinclair_NNP ._. Before_IN the_DT
        1990_CD s_VBZ ,_, “ people_NNS thought_VBD that_IN we_PRP were_VBD a_DT lot_NN like_IN cars_NNS ,_, that_IN we_PRP would_MD just_RB rust_NN and_CC
        breakdown—nothing_VBG we_PRP could_MD do_VB about_IN it_PRP ._. The_DT new_JJ idea_NN is_VBZ that_IN there_EX are_VBP pathways_NNS that_WDT can_MD
        boost_VB our_PRP$ defences_NNS against_IN ageing—the_NN ‘ ageing-can-be-regulated_JJ’ discovery_NN …_NN that_IN genes_NNS can_MD
        control_VB ageing_VBG [_NN and_CC ]_NN that_IN there_EX are_VBP pathways_NNS that_WDT [_NN we_PRP can_MD use_VB to_TO ]_NN slow_JJ down_RP the_DT process_NN ,_,”
        he_PRP says_VBZ ._. “ If_IN that_DT 's_VBZ true—and_NN it_PRP really_RB seems_VBZ to_TO be_VB true_JJ for_IN a_DT lot_NN of_IN organisms—if_NN it_PRP 's_VBZ true_JJ
        for_IN us_PRP ,_, it_PRP really_RB means_VBZ that_IN there_EX is_VBZ hope_VBP that_IN we_PRP will_MD be_VB able_JJ ,_, one_CD day_NN ,_, to_TO find_VB small_JJ
        molecules_NNS that_WDT can_MD alter_VB these_DT pathways_NNS ._.”
      
      
        How_WRB Long_NNP Could_MD We_PRP Live_NNP ?_.
        Sinclair_NNP expects_VBZ to_TO see_VB such_JJ developments_NNS within_IN his_PRP$ lifetime_NN ,_, but_CC he_PRP ridicules_VBZ the_DT
        notion_NN that_IN humans_NNS will_MD experience_VB anything_NN like_IN the_DT 70_CD %_NN extension_NN to_TO lifespan_NN of_IN his_PRP$
        cultured_JJ yeast_NN ._. “ It_PRP 'll_MD be_VB great_JJ if_IN we_PRP can_MD just_RB give_VB people_NNS an_DT extra_JJ five_CD years_NNS and_CC have_VBP
        less_JJR disease_NN in_IN their_PRP$ old_JJ age_NN and_CC make_VB it_PRP less_RBR painful_JJ ,_,” he_PRP says_VBZ ._. “ We_PRP wo_MD n't_RB be_VB seeing_VBG any_DT
        Methuselahs_NNP around_IN ,_,” he_PRP insists_VBZ ._.
        On_IN his_PRP$ side_NN are_VBP James_NNP Vaupel_NNP ,_, one_CD of_IN Europe_NNP 's_POS leading_VBG demographers_NNS ,_, and_CC Marc_NNP Mangel_NNP ,_, a_DT
        mathematical_JJ modeller_NN at_IN the_DT University_NNP of_IN California_NNP at_IN Santa_NNP Cruz_NNP ._. “ Since_IN 1840_CD ,_, life_NN
        expectancy_NN has_VBZ been_VBN going_VBG up_RP at_IN 2_CD ._. 5_CD years_NNS per_IN decade_NN and_CC will_MD continue_VB at_IN this_DT rate_NN ,_, maybe_RB
        a_DT little_JJ faster_RBR ,_,” says_VBZ Vaupel_NNP ,_, head_NN of_IN the_DT Laboratory_NNP of_IN Survival_NNP and_CC Longevity_NNP at_IN the_DT Max_NNP
        Planck_NNP Institute_NNP for_IN Demographic_NNP Research_NNP in_IN Rostock_NNP ,_, Germany_NNP ._. Women_NNS in_IN Japan_NNP currently_RB
        have_VBP the_DT highest_JJS average_NN life_NN expectancy_NN of_IN 85_CD ,_, he_PRP notes_VBZ :_: “ So_IN the_DT figure_NN could_MD be_VB 100_CD in_IN
        six_CD decades_NNS ,_, but_CC not_RB 500_CD ._.” There_EX 's_VBZ remarkably_RB little_JJ people_NNS can_MD do_VB even_RB if_IN they_PRP want_VBP to_TO
        live_VB as_RB long_RB as_IN possible_JJ ,_, he_PRP says_VBZ ._. “ Give_VB up_RB smoking_NN ,_, lose_VB weight_NN ,_, do_VBP n't_RB drive_VB when_WRB drunk_JJ ,_,
        install_VBP a_DT smoke_NN detector_NN ,_, take_VB regular_JJ exercise_NN ,_,” suggests_VBZ Vaupel_NNP ,_, who_WP insists_VBZ he_PRP does_VBZ them_PRP
        all_DT ,_, as_RB well_RB as_IN taking_VBG vitamin_NN supplements_NNS ._.
        
          
            “ You_PRP look_VBP at_IN these_DT worms_NNS and_CC think_VBP ,_, ‘ Oh_UH my_PRP$ God_NNP ,_, these_DT worms_NNS should_MD be_VB
            dead_JJ ._.’ But_CC they_PRP 're_VBP not_RB ._. They_PRP 're_VBP moving_VBG around_IN ._.”
          
        
        Mangel_NNP sees_VBZ the_DT problem_NN of_IN assessing_VBG the_DT limitations_NNS of_IN ageing_VBG research_NN as_RB fairly_RB
        straightforward_JJ ._. Mathematical_NNP models_NNS ,_, he_PRP says_VBZ ,_, could_MD solve_VB it_PRP by_IN linking_VBG demographic_JJ
        properties_NNS and_CC physiological_JJ developments_NNS ._. “ We_PRP 've_VBP had_VBD a_DT separation_NN of_IN the_DT biology_NN of_IN ageing_VBG
        and_CC the_DT demography_NN of_IN ageing_VBG ,_, and_CC they_PRP need_VBP to_TO come_VB together_RB again_RB ,_,” notes_NNS Mangel_NNP ,_, whose_WP$
        personal_JJ anti-ageing_JJ regime_NN involves_VBZ taking_VBG “ a_DT dose_NN of_IN anti-oxidant_JJ chocolate_NN with_IN a_DT good_JJ
        feeling_NN ._.”
        But_CC Cythnia_NNP Kenyon_NNP ,_, whose_WP$ laboratory_NN reported_VBD in_IN October_NNP that_IN it_PRP had_VBD generated_VBN a_DT 6_CD -_: fold_VB
        increase_NN in_IN the_DT lifespan_NN of_IN its_PRP$ nematodes_NNS ,_, is_VBZ not_RB so_RB sure_JJ about_IN the_DT limitations_NNS ._. “ You_PRP look_VBP
        at_IN these_DT worms_NNS and_CC think_VBP ,_, ‘ Oh_UH my_PRP$ God_NNP ,_, these_DT worms_NNS should_MD be_VB dead_JJ ._.’ But_CC they_PRP 're_VBP not_RB ._. They_PRP 're_VBP
        moving_VBG around_IN …_NN ._. Once_RB you_PRP get_VBP your_PRP$ brain_NN wrapped_VBD around_IN that_DT …_NN then_RB you_PRP start_VBP thinking_VBG ,_, oh_UH
        my_PRP$ goodness_NN ,_, so_RB lifespan_NN is_VBZ something_NN you_PRP can_MD change—it_NN 's_POS plastic_NN ._. Then_RB who_WP knows_VBZ what_WP the_DT
        limit_NN is_VBZ ?_.” (_( Cynthia_NNP Kenyon_NNP has_VBZ recorded_VBN video_NN clips_NNS of_IN the_DT superstars_NNS of_IN her_PRP$ lab_NN ,_, 
        Caenorhabditis_NNP elegans_NNS ,_, to_TO show_VB how_WRB long-lived_JJ mutant_JJ nematodes_NNS
        are_VBP as_RB vigorous_JJ as_IN normal_JJ young_JJ adults_NNS [_NN Videos_NNP 1_CD –_NN 4_CD ]_NN ._. )_)
        Warming_NNP to_TO the_DT theme_NN ,_, Kenyon_NNP hypothesises_NNS :_: “ If_IN you_PRP 'd_MD asked_VBD me_PRP many_JJ generations_NNS ago_RB ,_, when_WRB
        we_PRP were_VBD actually_RB common_JJ precursors_NNS of_IN worms_NNS and_CC flies_VBZ ,_, ‘ Cynthia_NNP ,_, you_PRP have_VBP a_DT two-week_JJ
        lifespan_NN ,_, do_VBP you_PRP think_VBP that_IN you_PRP could_MD [_NN live_VB longer_JJR ]_NN ?_.’ And_CC if_IN I_PRP 'd_MD told_VBD you_PRP ,_, ‘ Well_RB ,_, I_PRP think_VBP
        our_PRP$ descendants_NNS will_MD live_VB 1_CD ,_, 000_CD times_NNS longer_RBR ,_,’ you_PRP 'd_MD have_VB said_VBN ,_, ‘ Oh_UH ,_, come_VB on_IN !_.’ But_CC we_PRP do_VBP ._.
        It_PRP happened_VBD ,_,” she_PRP notes_VBZ ._.
        “ Who_WP knows_VBZ what_WP you_PRP could_MD do_VB in_IN people_NNS ?_.” Kenyon_NNP muses_NNS ._. “ I_PRP do_VBP n't_RB want_VB to_TO go_VB on_IN record_NN
        saying_VBG that_IN it_PRP 's_VBZ not_RB possible_JJ in_IN people_NNS because_IN I_PRP do_VBP n't_RB see_VB why_WRB it_PRP would_MD n't_RB be_VB …_NN ._. I_PRP 'm_VBP
        certainly_RB not_RB imagining_VBG that_IN my_PRP$ company_NN in_IN the_DT next_JJ few_JJ years_NNS is_VBZ going_VBG to_TO come_VB up_RP with_IN a_DT
        compound_NN that_WDT can_MD make_VB people_NNS live_JJ to_TO be_VB 500_CD ._. That_DT seems_VBZ just_RB preposterous_JJ ._.” So_IN the_DT
        timescale_NN is_VBZ millions_NNS of_IN years_NNS ?_. “ No_DT ,_, not_RB necessarily_RB ,_,” she_PRP insists_VBZ ,_, “ because_IN once_RB we_PRP
        understand_VBP the_DT mechanism_NN ,_, then_RB we_PRP can_MD intervene_VB and_CC see_VB what_WP we_PRP can_MD accomplish_VB ._.”
      
      
        Signalling_NNP Life_NNP and_CC Sweet_NNP 16_CD
        Kenyon_NNP ,_, professor_NN of_IN biochemistry_NN and_CC biophysics_NNS at_IN the_DT University_NNP of_IN California_NNP at_IN San_NNP
        Francisco_NNP ,_, is_VBZ among_IN the_DT key_JJ contributors_NNS responsible_JJ for_IN showing_VBG that_IN a_DT single_JJ gene_NN ,_, and_CC
        subsequently_RB many_JJ genes_NNS ,_, can_MD change_VB an_DT organism_NN 's_POS lifespan_NN ._.
        
          “ It_PRP is_VBZ inconceivable_JJ …_NN that_IN a_DT life-extending_JJ therapy_NN will_MD ever_RB be_VB developed_VBN that_WDT is_VBZ
          able_JJ to_TO extend_VB life_NN independent_JJ of_IN every_DT other_JJ change_NN ._.”
        
        In_IN a_DT seminal_NN paper_NN published_VBD a_DT decade_NN ago_RB ,_, Kenyon_NNP 's_POS laboratory_NN showed_VBD that_IN mutations_NNS in_IN
        the_DT 
        daf-_NN 2_CD gene_NN doubled_VBD the_DT lifespan_NN of_IN the_DT nematode_NN 
        C_NNP ._. elegans_NNS ._. 
        daf-_NN 2_CD encodes_NNS a_DT receptor_NN that_WDT is_VBZ similar_JJ to_TO those_DT for_IN insulin_NN and_CC
        insulin-like_JJ growth_NN factor-_NN 1_CD (_( IGF-_NNP 1_LS )_) in_IN humans_NNS ;_: this_DT hormone_NN receptor_NN normally_RB speeds_VBZ up_RP
        ageing_VBG in_IN worms_NNS ,_, but_CC the_DT mutations_NNS inhibit_VBP its_PRP$ action_NN and_CC enable_VB the_DT organisms_NNS to_TO live_VB
        longer_RBR ._. Before_IN the_DT results_NNS appeared_VBD ,_, there_EX was_VBD a_DT “ very_RB negative_JJ attitude_NN” towards_IN ageing_VBG
        research_NN ,_, recalls_VBZ Kenyon_NNP ._. Since_IN then_RB ,_, and_CC especially_RB over_IN the_DT past_JJ few_JJ years_NNS in_IN response_NN to_TO
        later_RB findings_NNS ,_, graduate_NN students_NNS have_VBP been_VBN scrambling_VBG for_IN a_DT chance_NN to_TO work_VB in_IN her_PRP$
        laboratory_NN ._. “ You_PRP ca_MD n't_RB believe_VB the_DT difference—there_NN was_VBD such_JJ resistance_NN to_TO it_PRP ,_,” she_PRP says_VBZ ._. “
        daf-_NN 2_CD made_VBD a_DT huge_JJ difference_NN ._.” But_CC then_RB so_RB did_VBD her_PRP$ subsequent_JJ research_NN in_IN
        the_DT field_NN ._.
        Among_IN her_PRP$ most_RBS significant_JJ findings_NNS is_VBZ the_DT identification_NN of_IN many_JJ more_JJR longevity_NN genes_NNS ;_:
        the_DT results_NNS ,_, published_VBN in_IN July_NNP ,_, derive_VB directly_RB from_IN her_PRP$ early_JJ work_NN on_IN 
        daf-_NN 2_CD ._. “ We_PRP discovered_VBD that_IN in_IN order_NN for_IN long-lived_JJ worms_NNS to_TO live_VB so_RB
        long_JJ ,_, they_PRP need_VBP another_DT gene_NN called_VBD 
        daf-_NN 16_CD ,_,” recalls_VBZ Kenyon_NNP ._. “
        daf-_NN 16_CD is_VBZ kind_NN of_IN the_DT opposite_NN of_IN 
        daf-_NN 2_CD ,_, in_IN the_DT sense_NN that_IN it_PRP promotes_VBZ longevity_NN and_CC youthfulness_NNS …_NN so_IN we_PRP
        call_VBP it_PRP ‘ sweet_JJ 16_CD ._.’” 
        daf-_NN 16_CD encodes_NNS a_DT transcription_NN factor_NN that_IN controls_VBZ the_DT expression_NN of_IN
        more_JJR than_IN 100_CD genes_NNS ._. “ They_PRP do_VBP n't_RB do_VB just_RB one_CD thing_NN ,_, they_PRP do_VBP many_RB things_NNS ,_,” says_VBZ Kenyon_NNP ._. They_PRP
        can_MD act_VB as_IN anti-oxidants_JJ (_( to_TO prevent_VB damage_NN from_IN oxygen_NN radicals_NNS )_) ,_, as_IN chaperones_NNS (_( to_TO
        prevent_VB misfolded_JJ proteins_NNS from_IN forming_VBG aggregates_NNS )_) ,_, as_IN antimicrobials_NNS (_( to_TO protect_VB against_IN
        bacteria_NNS and_CC fungi_NNS )_) ,_, and_CC as_IN metabolic_JJ agents_NNS ._.
        “ So_IN the_DT picture_NN that_WDT emerges_VBZ is_VBZ that_IN the_DT way_NN the_DT insulin_NN /_NN IGF-_NNP 1_CD hormone_NN system_NN produces_VBZ
        these_DT enormous_JJ effects_NNS on_IN lifespan_NN is_VBZ by_IN coordinating_VBG the_DT expression_NN of_IN many_JJ genes_NNS that_WDT do_VBP
        different_JJ things_NNS to_TO affect_VB lifespan_NN ,_, each_DT of_IN which_WDT on_IN its_PRP$ own_JJ has_VBZ only_RB a_DT small_JJ effect_NN ,_,”
        notes_NNS Kenyon_NNP ._. “ It_PRP 's_VBZ as_IN though_IN 
        daf-_NN 2_CD and_CC 
        daf-_NN 16_CD ,_, the_DT regulators_NNS ,_, would_MD be_VB the_DT conductors_NNS of_IN an_DT orchestra_NN ._. They_PRP
        bring_VBP together_RB the_DT flutes_NNS and_CC the_DT violins_NNS and_CC the_DT French_JJ horns_NNS ,_, each_DT of_IN which_WDT do_VBP different_JJ
        things_NNS ,_, and_CC they_PRP make_VBP them_PRP all_DT work_NN together_RB in_IN concert_NN ._.”
        Kenyon_NNP is_VBZ unequivocal_NN about_IN the_DT bottom_JJ line_NN :_: “ Now_RB we_PRP have_VBP a_DT whole_JJ set_NN of_IN genes_NNS whose_WP$
        biochemical_JJ functions_NNS we_PRP can_MD be_VB working_VBG on_IN to_TO understand_VB more_JJR about_IN the_DT actual_JJ mechanisms_NNS
        of_IN ageing_VBG ._.” Complementary_NNP results_NNS in_IN flies_VBZ and_CC mammals_NNS persuade_VB her_PRP to_TO be_VB more_RBR explicit_JJ ._.
        “ The_DT common_JJ ancestor_NN of_IN worms_NNS ,_, flies_VBZ ,_, and_CC mice_NNS must_MD have_VB had_VBN an_DT insulin_NN /_NN IGF-_NNP 1_CD -_: like_IN hormone_NN
        system_NN that_WDT controlled_VBD ageing_VBG ._. And_CC that_DT ability_NN has_VBZ been_VBN maintained_VBN ._. So_IN the_DT question_NN is_VBZ ,_,
        has_VBZ [_NN that_DT ability_NN ]_NN been_VBN lost_VBN in_IN humans_NNS ?_. I_PRP think_VBP it_PRP 's_VBZ quite_RB likely_JJ that_IN it_PRP will_MD also_RB
        function_VB in_IN humans_NNS ,_, but_CC there_EX is_VBZ n't_RB a_DT direct_JJ demonstration_NN yet_RB that_IN that_DT 's_VBZ the_DT case_NN ._.”
        Nevertheless_RB ,_, the_DT discoveries_NNS about_IN the_DT role_NN of_IN the_DT insulin_NN /_NN IGF-_NNP 1_CD pathway_NN in_IN ageing_VBG have_VBP
        had_VBD a_DT profound_JJ impact_NN on_IN her_PRP$ own_JJ lifestyle_NN ,_, which_WDT includes_VBZ a_DT tendency_NN to_TO discard_VB the_DT bread_NN
        from_IN sandwiches_NNS and_CC eat_VB only_RB the_DT toppings_NNS of_IN pizzas_NNS (_( Box_NNP 2_LS )_) ._. “ I_PRP 'm_VBP on_IN a_DT low-carb_JJ diet_NN ._. I_PRP
        gave_VBD my_PRP$ worms_NNS glucose_NN ,_, and_CC it_PRP shortened_VBN their_PRP$ lifespan_NN ._. [_NN The_DT diet_NN ]_NN makes_VBZ sense_NN because_IN it_PRP
        keeps_VBZ your_PRP$ insulin_NN levels_NNS down_RB ,_,” she_PRP says_VBZ ._.
        “ Caloric_NNP restriction_NN extends_VBZ lifespan_NN of_IN mice_NNS ,_, and_CC so_RB does_VBZ the_DT insulin_NN /_NN IGF-_NNP 1_CD pathway_NN ,_,”
        she_PRP notes_VBZ ._. Indeed_RB ,_, starting_VBG a_DT low-calorie_JJ diet_NN at_IN any_DT point_NN in_IN adulthood_NN appears_VBZ to_TO help_VB
        fruit_NN flies_VBZ live_VB longer_RB ,_, according_VBG to_TO research_NN in_IN Britain_NNP published_VBD last_JJ September_NNP ._. “ What_WP
        we_PRP do_VBP n't_RB know_VB for_IN sure_JJ in_IN mice_NNS ,_,” Kenyon_NNP continues_VBZ ,_, “ is_VBZ whether_IN the_DT two_CD pathways_NNS are_VBP
        different_JJ or_CC the_DT same_JJ ._.”
        While_IN much_JJ ageing_VBG research_NN focuses_VBZ on_IN these_DT two_CD influences_VBZ ,_, she_PRP says_VBZ that_IN there_EX are_VBP
        another_DT two_CD areas_NNS of_IN investigation_NN ._. Her_PRP$ laboratory_NN reported_VBD in_IN December_NNP 2002_CD that_IN
        inhibiting_VBG the_DT respiration_NN of_IN mitochondria_NN in_IN developing_VBG worms_NNS increased_VBD longevity_NN ,_, but_CC
        that_IN it_PRP had_VBD no_DT effect_NN in_IN adult_NN worms_NNS ,_, for_IN reasons_NNS still_RB unexplained_JJ ,_, she_PRP says_VBZ ._. Further_RB
        microarray_NN analysis_NN is_VBZ underway_NN to_TO pinpoint_VB whether_IN the_DT cause_NN simply_RB lies_VBZ downstream_JJ of_IN the_DT
        insulin_NN /_NN IGF-_NNP 1_CD pathway_NN or_CC whether_IN it_PRP is_VBZ something_NN different_JJ altogether_RB ._.
      
      
        The_DT Price_NNP of_IN Life_NNP
        Then_RB there_EX 's_VBZ research_NN looking_VBG at_IN the_DT effects_NNS on_IN lifespan_NN of_IN changes_NNS to_TO an_DT organism_NN 's_POS
        reproductive_JJ system_NN ._. For_IN Kenyon_NNP ,_, such_JJ work_NN often_RB involves_VBZ a_DT battle_NN to_TO convince_VB sceptics_NNS
        that_WDT longevity_NN is_VBZ not_RB a_DT trade-off_NN with_IN fertility_NN ._. Four_CD years_NNS ago_RB ,_, her_PRP$ laboratory_NN reported_VBD
        that_IN killing_VBG germ_NN cells_NNS increases_VBZ the_DT lifespan_NN of_IN worms_NNS by_IN 60_CD %_NN ,_, but_CC only_RB because_RB ,_, she_PRP
        stresses_VBZ ,_, it_PRP affects_VBZ endocrine_NN signalling_VBG and_CC not_RB because_IN it_PRP prevents_VBZ reproduction_NN ._. Further_RB
        research_NN ,_, published_VBD last_JJ year_NN ,_, showed_VBD quite_RB clearly_RB ,_, she_PRP says_VBZ ,_, that_IN ageing_VBG and_CC reproduction_NN
        are_VBP controlled_VBN independently_RB of_IN one_CD another_DT ._. And_CC as_IN for_IN her_PRP$ recent_JJ work_NN on_IN infertile_JJ worms_NNS ,_,
        which_WDT lived_VBD six_CD times_NNS as_RB long_RB as_IN normal_JJ following_NN the_DT removal_NN of_IN their_PRP$ entire_JJ reproductive_JJ
        systems_NNS ,_, she_PRP says_VBZ :_: “ If_IN we_PRP could_MD intervene_VB in_IN the_DT hormone_NN signalling_VBG pathways_NNS directly_RB ,_, we_PRP
        think_VBP the_DT animals_NNS would_MD still_RB live_VB six_CD times_NNS as_RB long_RB as_IN normal_JJ ,_, but_CC would_MD be_VB fertile_JJ as_IN
        well_RB ._.”
        Jim_NNP Carey_NNP is_VBZ one_CD of_IN those_DT “ trade-off_NN” sceptics_NNS ._. He_PRP is_VBZ a_DT population_NN biologist_NN at_IN the_DT
        University_NNP of_IN California_NNP at_IN Davis_NNP and_CC his_PRP$ research_NN ,_, on_IN the_DT effect_NN on_IN life_NN expectancy_NN of_IN
        replacing_VBG the_DT ovaries_NNS of_IN old_JJ mice_NNS with_IN ovaries_NNS from_IN younger_JJR mice_NNS ,_, is_VBZ intended_VBN to_TO complement_VB
        Kenyon_NNP 's_POS work_NN ._. But_CC he_PRP insists_VBZ that_IN “ an_DT honest_JJ discussion_NN of_IN lifespan_NN extension_NN must_MD include_VB
        consideration_NN of_IN tradeoffs_NNS ._.” Many_JJ manipulations_NNS that_WDT extend_VBP lifespan_NN in_IN model_NN systems_NNS ,_,
        whether_IN genetic_JJ or_CC dietary_JJ ,_, for_IN example_NN ,_, ignore_VB or_CC gloss_VBP over_IN the_DT side_NN effects_NNS ,_, such_JJ as_IN
        permanent_JJ sterility_NN ,_, huge_JJ weight_NN loss_NN ,_, distorted_JJ organ-to-body_JJ ratios_NNS ,_, or_CC major_JJ behavioural_NN
        aberrations_NNS ,_, he_PRP notes_VBZ ._. “ It_PRP is_VBZ inconceivable_JJ to_TO me_PRP that_IN a_DT life-extending_JJ therapy_NN will_MD ever_RB
        be_VB developed_VBN that_WDT is_VBZ able_JJ to_TO extend_VB life_NN independent_JJ of_IN every_DT other_JJ change_NN ,_,” he_PRP concludes_VBZ ._.
        “ All_DT life_NN systems_NNS are_VBP interlinked_JJ and_CC hierarchically_RB integrated_VBN at_IN all_DT levels_NNS ,_, so_RB to_TO talk_VB
        about_IN life_NN extension_NN using_VBG analogies_NNS with_IN a_DT car_NN warranty_NN concept_NN is_VBZ wrong-headed_JJ ._.”
        Another_DT “ trade-off_NN” sceptic_JJ takes_VBZ a_DT different_JJ tack_NN ._. As_IN Armand_NNP Leroi_NNP puts_VBZ it_PRP :_: “ During_IN
        occasional_JJ periods_NNS of_IN involuntary_JJ celibacy_NN I_PRP have_VBP thought_VBN ,_, well_RB ,_, I_PRP may_MD not_RB be_VB getting_VBG laid_VBN ,_,
        but_CC at_IN least_JJS I_PRP shall_MD live_RB to_TO a_DT miserable_JJ and_CC solitary_JJ old_JJ age_NN ._.” Leroi_NNP ,_, an_DT evolutionary_JJ
        biologist_NN at_IN Imperial_NNP College_NNP of_IN Science_NNP ,_, Technology_NNP ,_, and_CC Medicine_NNP in_IN London_NNP ,_, offers_VBZ an_DT
        optimistic_JJ appraisal_NN of_IN the_DT chances_NNS of_IN finding_VBG a_DT cure_NN for_IN ageing_VBG in_IN his_PRP$ new_JJ book_NN about_IN the_DT
        effects_NNS of_IN genetic_JJ variety_NN on_IN the_DT human_JJ body_NN ._. He_PRP sees_VBZ ageing_VBG simply_RB as_IN a_DT collection_NN of_IN
        curable_JJ diseases_NNS :_: “ There_EX is_VBZ no_DT obvious_JJ impediment_NN to_TO that_DT advance_NN ,_, nothing_NN to_TO make_VB us_PRP think_VBP
        that_IN human_JJ beings_NNS have_VBP a_DT fixed_VBN lifespan_NN ._.”
      
    
  
